SB 5915
SignedSenate
Health technology assessment
Concerning the health technology assessment program.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill updates Washington’s health technology assessment program to improve how the state evaluates new medical devices, drugs, or procedures for coverage in state health programs. It strengthens evidence review standards, adds transparency and public input, and sets deadlines for decision-making. It also prioritizes technologies used in Medicare or national guidelines and requires special consideration for rare or life-threatening conditions.
- The health technology clinical committee will review up to six technologies in the first year and up to eight in the second year after June 7, 2006, with priority given to technologies used in Medicare, recommended in national guidelines, or with high state costs or safety/efficacy concerns.
- Covered technologies must be reevaluated at least every 18 months, and only new evidence (not re-evaluating prior evidence) can be used in rereviews.
- The committee may review technologies not initially selected if an interested party submits a petition, and the administrator must contract with an evidence-based practice center (e.g., an AHRQ-designated center) to conduct a systematic review.
- Assessments must consider evidence from state agencies, public submissions, and unique impacts on specific populations (e.g., by sex, race, age, or disability), and must prioritize the most valid and reliable evidence.
- For life-threatening or rare diseases, the committee must review peer-reviewed clinical trials, and may consider expert input if randomized trials are unethical or impossible.
- The Health Care Authority must publish submissions for new assessments on its website within 30 days, and the committee must issue a determination (or explain an adverse decision) within 180 days of submission.
Who is affected
- State health programs (e.g., Medicaid) — State-run health programs (like Medicaid) may adjust coverage decisions based on the committee's determinations, potentially limiting or expanding access to certain technologies.
- Patients with life-threatening or rare diseases — Patients with life-threatening or rare diseases may gain or lose access to new treatments depending on whether the technology is deemed safe, effective, and cost-effective for coverage.
- Healthcare providers — Hospitals, clinics, and providers who use or plan to use the evaluated technologies may need to adjust clinical practices or billing based on coverage decisions.
- Health technology manufacturers — Manufacturers or developers of the health technologies may need to submit evidence or adjust marketing strategies based on assessment outcomes.
- State health plan enrollees — Residents enrolled in state-purchased health plans may be affected if coverage for a technology changes, potentially impacting out-of-pocket costs or access to care.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Mandating that assessments give greatest weight to the most valid and reliable evidence—including study design, consistency, and empirical rigor—reduces reliance on low-quality or industry-funded data, improving the clinical accuracy and public trust in coverage decisions.
HealthcarePeopleRef: Sec. 1(4)(d)(i)Public comment and submission of evidence by interested parties—including patient advocates, clinicians, and researchers—enhances transparency and democratic input, helping ensure coverage decisions reflect real-world patient experiences and community values.
HealthcarePeopleRef: Sec. 2(2)(b) & Sec. 1(4)(c)The 180-day deadline for determinations and 30-day public posting requirement creates accountability and predictability, reducing delays that currently plague coverage decisions and enabling faster access to approved technologies for patients and providers.
HealthcarePeopleRef: Sec. 2(4)Prioritizing technologies already used in Medicare or recommended in national guidelines aligns Washington’s coverage decisions with national standards, reducing administrative burden and improving consistency for providers and patients who navigate multiple health plans.
HealthcarePeopleRef: Sec. 1(1)(a)Allowing expert input when RCTs are unethical or impossible for rare/life-threatening conditions provides flexibility to evaluate innovative therapies (e.g., CAR-T, gene therapies) without waiting for years of trial data—accelerating access for high-need populations.
HealthcarePeopleRef: Sec. 1(5)(b)
Potential Concerns (5)
By prioritizing technologies with high state expenditures or safety/efficacy concerns, the bill enables coverage restrictions that could delay or deny access to expensive but clinically beneficial treatments—especially for rare or life-threatening conditions—potentially increasing out-of-pocket costs or forcing patients to seek care out-of-state.
HealthcarePeopleRef: Sec. 1(1)(b)(ii)Requiring rereviews only on *new* evidence (not re-evaluating prior assumptions) may lock in outdated coverage decisions if earlier evidence was flawed or incomplete—hurting patients who rely on evolving clinical standards and limiting corrective adjustments over time.
HealthcarePeopleRef: Sec. 1(2)While the bill mandates consideration of impacts on specific populations (e.g., race, disability), it does not require stratified analysis or enforceable equity outcomes—meaning such input may be acknowledged but not prioritized in final determinations, reducing real-world impact for marginalized groups.
HealthcareLean peopleRef: Sec. 1(4)(d)(ii)Mandating peer-reviewed clinical trials—including RCTs—for life-threatening or rare diseases may exclude promising but less-studied therapies (e.g., gene therapies, orphan drugs) where RCTs are ethically or practically infeasible, delaying access for patients with few alternatives.
HealthcarePeopleRef: Sec. 1(5)(a)Requiring determinations to be *consistent* with Medicare and national guidelines unless *substantial* evidence supports deviation creates a high bar for divergent decisions—effectively locking Washington into federal or industry-aligned coverage policies that may not reflect local patient needs or cost structures.
HealthcarePeopleRef: Sec. 2(3)
Who Is Most Affected
Medicaid and other state health program enrollees—especially those with rare or life-threatening conditions—may benefit from faster, more transparent coverage decisions, but could be harmed if technologies are excluded due to cost-effectiveness thresholds or lack of RCT data.
Patients with rare or life-threatening diseases gain from accelerated review processes and flexibility for non-RCT evidence, but may be disadvantaged if coverage determinations require high evidentiary bars that exclude emerging therapies.
Healthcare providers benefit from clearer, more consistent coverage criteria and reduced administrative uncertainty, but may face pressure to adopt or discontinue technologies based on state determinations rather than clinical judgment.
Manufacturers of high-cost or innovative technologies may face longer or more rigorous review timelines, but gain predictability and transparency in the process; those with strong evidence and alignment to Medicare guidelines will benefit most.
State agencies (e.g., HCA, DOH) gain standardized, evidence-based coverage guidance that reduces liability and improves budget predictability, but may lose flexibility to cover technologies outside federal guidelines.